FUNDING ORGANIZATION	RESEARCH ORGANIZATION	PROGRAM	DIRECTOR	CITY	COUNTRY	ABSTRACT
	CANADA - CHVI	UGANDA VIRUS RESEARCH INSTITUTE (UVRI)	GLOBAL HEALTH RESEARCH INITIATIVE	KALEEBU, PONTIANO	ENTEBBE	UGANDA
	MRC	UGANDA VIRUS RESEARCH INSTITUTE (UVRI)	A RANDOMISED TRIAL OF MONITORING PRACTICE AND PULSE ANTIRETROVIRAL THERAPY IN AFRICAN CHILDREN WITH HIV INFECTION (ARROW TRIAL)	MUGYENYI, P	ENTEBBE	UGANDA	View
Junior DART is a randomised open-label trial enrolling 1200 African HIV-infected children, aged 6 months to 18 years, with an adult carer in the DART (Development of AntiRetroviral Therapy) trial which has enrolled 2000 of 3000 adults in Uganda (2 sites) and Zimbabwe (1 site). Junior DART will take place in the same sites and the 2 trial teams will work closely together. Junior DART will have two major randomisations: to clinical monitoring only (CMO) versus laboratory and clinical monitoring (LCM); and to intermittent (planned treatment interruptions, PTI) versus continuous ART. In a further randomised substudy, 3 regimen strategies for initiating ART will be compared in terms of HIV RNA viral load response. Eligible children should have paediatric WHO Stage 2 or 3 disease, and CD4 percent 20% for children 2 years, 15% for children 2-11 years, or CD4 count 200 cells/mm3 for those aged 12-18 years. It is expected that at least 750 children randomised to CMO versus LCM will be 2 years and have achieved a sufficient increase in CD4 (CD4 ?20% for 2-11 years and CD4 250 cells/mm3 for 12-18 years) by 48 or 72 weeks to be eligible for the second randomisation to PTI versus continuous ART. This will only open after a non-randomised pilot study of PTIs in 100 children satisfying these threshold criteria has been completed (with all children having monthly CD4 measurements) and the DSMC and Trial Steering Committee have assessed the safety of the proposed PTI strategy. Recruitment into the trial will take place over one year with minimum follow-up of 4 years. First and second-line ART will be available for all children (for up to five years). The decision to change to second-line ART will be based on clinical criteria alone for the CMO arm and on clinical plus laboratory criteria for the LCM arm. Issues of after-trial ART are being negotiated with governments in the same way as for adult DART. The primary efficacy endpoint will be progression to a new paediatric WHO stage 3 (AIDS) event or death in children under 13 years, or adult WHO stage 4 disease for those 13 years and older. The primary outcome for the randomised substudy will be change in HIV RNA from baseline to 48 weeks, performed retrospectively on stored plasma samples.
	NIH	UGANDA VIRUS RESEARCH INSTITUTE (UVRI)	HIV/HAART AND PREGNANCY/CONTRACEPTION IN RAKAI, UGANDA	KAGAAYI, JOSEPH	ENTEBBE	UGANDA	View
	NIH	UGANDA VIRUS RESEARCH INSTITUTE (UVRI)	CIRCUMCISION: HIV/STIS AND BEHAVIORS IN A RCT AND POST-RCT SURVEILLANCE; RAKAI	SERWADDA, DAVID	ENTEBBE	UGANDA	View
	NIH	UGANDA VIRUS RESEARCH INSTITUTE (UVRI)	GENITAL ANAEROBES, INFLAMMATION AND HIV RISK; RAKAI	SERWADDA, DAVID	ENTEBBE	UGANDA	View
	NIH	UGANDA VIRUS RESEARCH INSTITUTE (UVRI)	HIV/AIDS INTERNATIONAL TRAINING PROGRAM	KALEEBU, PONTIANO	ENTEBBE	UGANDA	View
	NIH	UGANDA VIRUS RESEARCH INSTITUTE (UVRI)	HOST GENETIC EPIDEMIOLOGY IN HIV-1-DISCORDANT AFRICAN COUPLES AND OTHER COHORTS	SERWADDA, DAVID	ENTEBBE	UGANDA	View
	NIH	UGANDA VIRUS RESEARCH INSTITUTE (UVRI)	PROTEOMICS CORE	KALEEBU, PONTIANO	ENTEBBE	UGANDA	View
	NIH	UGANDA VIRUS RESEARCH INSTITUTE (UVRI)	TRANSMISSION OF KSHV/HHV-8 IN SOUTH AFRICA	MBIDDE, EDWARD	ENTEBBE	UGANDA	View
	NIH	UGANDA VIRUS RESEARCH INSTITUTE (UVRI)	UGANDA HIV/TB COHRE TRAINING PROGRAM	MBIDDE, EDWARD KATONGOLE	ENTEBBE	UGANDA	View
	NIH	UGANDA VIRUS RESEARCH INSTITUTE (UVRI)	UGANDA HIV/TB COHRE TRAINING PROGRAM	KALEEBU, PONTIANO	ENTEBBE	UGANDA	View
	Wellcome	UGANDA VIRUS RESEARCH INSTITUTE (UVRI)	HELMINTHS AND ALLERGY IN UGANDA.	ELLIOTT, PROF ALISON M ELLIOTT	ENTEBBE	UGANDA
	Wellcome	UGANDA VIRUS RESEARCH INSTITUTE (UVRI)	IMPROVING ACCESS AND QUALITY OF DATA FROM A LONGITUDINAL HIV COHORT IN UGANDA .	LEVIN, DR JONATHAN B	ENTEBBE	UGANDA	View
The main aim is to reorganise the existing population-based database of 42,000 people to enable better access and usage for analyses. The database contains 19 years of demographic, household, social, medical and serological data from members of a rural Ugandan cohort, with 18,000 people currently uncer follow up. The proposed fully relational database with a new composite structure will be able to define new entities of importance within the database, and link existing data and new data from ot her studies. The primary purpose is to enhance data access for many new analyses, by both MRC researchers and external collaborative researchers, and will facilitate a greater sharing of the data within the scientific community and greater scientific output from the cohort. The new database structure will also improve data collection techniques for future surveys. A secondary, but important objective is to develop database programming capacity within Uganda, by training and mentoring program mers to an international standard.
	Wellcome	UGANDA VIRUS RESEARCH INSTITUTE (UVRI)	PARTNER INSTITUTION - TRAINING HEALTH RESEARCHERS INTO VOCATIONAL EXCELLENCE IN EAST AFRICA (THRIVE).	SEWANKAMBO, PROF NELSON	ENTEBBE	UGANDA